Warm autoimmune hemolytic anemia (WAIHA), resulting from pathogenic RBC autoantibodies, is a severe and sometimes fatal disease. WAIHA presents numerous diagnostic and transfusion complexities for the blood bank. Treatment strategies have variable success, with relapse rates as high as 50%. Although >50% of AIHA cases are idiopathic, secondary AIHA occurs in various settings, more recently reported with SARS-CoV-2, cancer immunotherapy, and hematopoietic stem cell transplant. While no licensed treatments specific for AIHA exist, and few approaches produce treatment-free durable remissions, new therapeutics (i.e., anti-FcRn) are currently being tested. Insights from novel AIHA murine models have elucidated mechanistic underpinnings that may provide additional therapeutic targets. This session will discuss the current WAIHA clinical landscape, including new insights into pathogenesis, clinical settings, novel therapeutic approaches, and new translational findings from AIHA murine models.
Discuss the current clinical landscape for warm AIHA, with an emphasis on recent developments in pathogenesis including checkpoint inhibitors and SARS-CoV-2
Review new clinical approaches to AIHA diagnosis, management and treatment, including transfusion therapy
Describe findings from new AIHA murine models and applicability to human disease